Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_3

33%

Ph phase_4

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Withdrawn1

Completed1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

withdrawn133%

completed133%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

NCT03318874

terminatedphase_3

Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects

NCT01746602

withdrawnnot_applicable

Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials

NCT01546012

Clinical Trials (3)

Showing 3 of 3 trials

NCT03318874Phase 4

Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction

Completed

NCT01746602Phase 3

Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects

Terminated

NCT01546012Not Applicable

Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3